Drug Discovery & Development - March 31, 2011
CAMBRIDGE, Mass. (AP) - Vertex Pharmaceuticals Inc. said that a potential hepatitis C treatment was safe and tolerable in a midstage study.
The study involved a combination of telaprevir and VX-222 with pegylated-interferon and ribavirin and focused on people with genotype 1 chronic hepatitis C who were new to treatment. Pegylated-interferon and ribavirin are already used to treat hepatitis C.
Previously, the company halted other arms of its telaprevir and VX-222 study because the combination wasn't working.
Telaprevir is Vertex's primary drug candidate.
Date: March 31, 2011
Source: Associated Press
The study involved a combination of telaprevir and VX-222 with pegylated-interferon and ribavirin and focused on people with genotype 1 chronic hepatitis C who were new to treatment. Pegylated-interferon and ribavirin are already used to treat hepatitis C.
Previously, the company halted other arms of its telaprevir and VX-222 study because the combination wasn't working.
Telaprevir is Vertex's primary drug candidate.
Date: March 31, 2011
Source: Associated Press
No hay comentarios:
Publicar un comentario